Table 3. Total Costs, QALY, and ICER.
| Base Case and Sensitivity Analyses | Cost, $ | QALY | ICER, $ | VBP, $a | ||
|---|---|---|---|---|---|---|
| Total | Incremental | Total | Incremental | |||
| Base case, full list price, US clinical practice | ||||||
| Standard therapy alone | 234 877 | NA | 7.23 | NA | NA | NA |
| Evolocumab added to standard therapy | 340 275 | 105 398 | 7.62 | 0.39 | 268 637 | 9669 |
| Discounted net price, US clinical practice | ||||||
| Standard therapy alone | 234 877 | NA | 7.23 | NA | NA | NA |
| Evolocumab added to standard therapy | 299 884 | 65 007 | 7.62 | 0.39 | 165 689 | 9669 |
| Full list price, FOURIER trial participants | ||||||
| Standard therapy alone | 228 015 | NA | 9.59 | NA | NA | NA |
| Evolocumab added to standard therapy | 367 833 | 139 817 | 9.93 | 0.34 | 413 579 | 6780 |
| Discounted net price, FOURIER trial participants | ||||||
| Standard therapy alone | 228 015 | NA | 9.59 | NA | NA | NA |
| Evolocumab added to standard therapy | 319 358 | 91 343 | 9.93 | 0.34 | 270 192 | 6780 |
Abbreviations: FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-years; VBP, value-based price.
a
Value-based price is net annual price to achieve an incremental cost-effectiveness ratio of $150 000 per quality-adjusted life-years.